Glucagon-like peptide-1 (GLP-1) mimetics: A new treatment for Alzheimer’s disease?;Análogos del Glucagon-like peptide-1 (GLP-1): ¿una nueva estrategia de tratamiento para la enfermedad de Alzheimer?

Revista de Neurologia

Volumn 59, Issue 11, 2014, Pages 517-524

  García Casares, Natalia ^a   García Arnés, Juan Antonio ^b   Gómez Huelgas, Ricardo ^a,c   Valdivielso Felices, Pedro ^a,d   García Arias, Carlota ^a   González Santos, Pedro ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b Unidad de Gestión Clínica de Laboratorio   (Spain)

^c Unidad de Gestión Clínica de Medicina Preventiva y Salud Pública   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Alzheimer s disease; Cognitive impairment; Dementia; Glucagon like peptide 1 (GLP 1); Type 2 diabetes

Indexed keywords

AMYLOID BETA PROTEIN; GLUCAGON LIKE PEPTIDE 1; ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INCRETIN; LIRAGLUTIDE; NEUROPROTECTIVE AGENT; PEPTIDE; VENOM; ZP10A PEPTIDE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEMENTIA; HUMAN; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; SYSTEMATIC REVIEW; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; BRAIN CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG SCREENING; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN CHEMISTRY; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; MODELS, NEUROLOGICAL; NEUROPROTECTIVE AGENTS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; RISK FACTORS; VENOMS;

EID: 84916604386     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5911.2014023     Document Type: Article

References (74)

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63,75.
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-21.
3. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009; 32: 221-6.
4. Yaffe K, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, Satterfield S, et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 2012; 69: 1170-5.
5. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007; 64: 570-5.
6. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
7. Yaffe K, Lindquist K, Schwartz AV, Vitartas C, Vittinghoff E, Satterfield S, et al. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 2011; 77: 1351-6.
8. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010; 75: 1195-202.
9. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-92.
10. Craft S. Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007; 4: 147-52.
11. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-78.
12. Spauwen PJ, Köhler S, Verhey FR, Stehouwer CD, Van Boxtel MP. Effects of type 2 diabetes on 12-year cognitive change: results from the Maastricht Aging Study. Diabetes Care 2013; 36: 1554-61.
13. Van den Berg E, Reijmer YD, De Bresser J, Kessels RP, Kappelle LJ, Biessels GJ, et al. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia 2010; 53: 58-65.
14. Sullivan MD, Katon WJ, Lovato LC, Miller ME, Murray AM, Horowitz KR, et al. Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. JAMA Psychiatry 2013; 70: 1041-7.
15. Castillo-Quan JI, Barrera-Buenfil DJ, Pérez-Osorio JM, Álvarez-Cervera FJ. Depresión y diabetes: de la epidemiología a la neurobiología. Rev Neurol 2010; 51: 347-59.
16. Brundel M, Van den Heuvel M, De Bresser J, Kappelle LJ, Biessels GJ, Utrecht Diabetic Encephalopathy Study Group. Cerebral cortical thickness in patients with type 2 diabetes. J Neurol Sci 2010; 299: 126-30.
17. Hoogenboom WS, Marder TJ, Flores VL, Huisman S, Eaton HP, Schneiderman JS, et al. Cerebral white matter integrity and resting-state functional connectivity in middle-aged patients with type 2 diabetes. Diabetes 2013; Nov 7. [Epub ahead of print].
18. De Bresser J, Tiehuis AM, Van den Berg E, Reijmer YD, Jongen C, Kappelle LJ, et al. Progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes. Diabetes Care 2010; 33: 1309-14.
19. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early T2DM. Arch Neurol 2011; 68: 51-7.
20. Manschot SM, Brands AM, Van der Grond J, Kessels RP, Algra A, Kappelle LJ, et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with T2DM. Diabetes 2006; 55: 1106-13.
21. Van Elderen SG, De Roos A, De Craen AJ, Westendorp RG, Blauw GJ, Jukema JW, et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology 2010; 75: 997-1002.
22. García-Casares N, Berthier ML, Jorge RE, González-Alegre P, Cardo AG, Rioja J, et al. Structural and functional brain changes in middle-aged type 2 diabetic patients: a cross-sectional study. J Alzheimers Dis 2014; Jan 21. [Epub ahead of print]
23. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010; 75: 764-70.
24. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316-38.
25. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, De la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 2006; 9: 13-33.
26. De la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res 2012; 9: 35-66.
27. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007; 56: 1817-24.
28. Yang Y, Ma D, Wang Y, Jiang T, Hu S, Zhang M, et al. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. J Alzheimers Dis 2013; 33: 329-38
29. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70: 440-8.
30. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dosedependently modulates verbal memory and plasma amyloidbeta in memory-impaired older adults. J Alzheimers Dis 2008; 13: 323-31.
31. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive imp irment: a pilot clinical trial. Arch Neurol 2012; 69: 29-38.
32. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902; 28: 325-53.
33. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-8.
34. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-40.
35. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48: 736-43.
36. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-9.
37. Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta 2013; 1832: 527-41.
38. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-39.
39. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
40. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer’s disease. Curr Alzheimer Res 2005; 2: 377-85.
41. Hamilton A, Holscher C. Receptors for the incretin glucagonlike peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009; 20: 1161-6.
42. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-9.
43. Merchenthaler I, Lane M, Shughrue P. Distribution of prepro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999; 403: 261-80.
44. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003; 27: 313-8.
45. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutida and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012; 13: 33.
46. Lee CS, Sund NJ, Vatamaniuk MZ, Matschinsky FM, Stoffers DA, Kaestner KH. Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo. Diabetes 2002; 51: 2546-51.
47. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-8.
48. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42: 856-64.
49. Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O’Harte FP. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys 2004; 428: 136-43.
50. Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 2003; 55: 105-31.
51. Zucker RS. Calcium-and activity-dependent synaptic plasticity. Curr Opin Neurobiol 1999; 9: 305-13.
52. Fagni L, Bossu JL, Bockaert J. Activation of a large-conductance Ca2+-dependent K+ channel by stimulation of glutamate phosphoinositide-coupled receptors in cultured cerebellar granule cells. Eur J Neurosci 1991; 3: 778-89.
53. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer’s disease. Recent Pat CNS Drug Discov 2010; 5: 109-17.
54. Holscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer’s disease? Neurobiol Aging 2010; 31: 1495-502.
55. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 2010; 19: 1205-19.
56. Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, et al. Exenatida promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis 2013; 4: e612.
57. Newington JT, Pitts A, Chien A, Arseneault R, Schubert D, Cumming RC. Amyloid beta resistance in nerve cell lines is mediated by the Warburg effect. PLoS One 2011; 6: e19191.
58. Newington JT, Rappon T, Albers S, Wong DY, Rylett RJ, Cumming RC. Overexpression of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase A in nerve cells confers resistance to amyloid β and other toxins by decreasing mitochondrial respiration and reactive oxygen species production. J Biol Chem 2012; 287: 37245-58.
59. Isacson R, Nielsen E, Dannaeus K, Bertilsson G, Patrone C, Zachrisson O, et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 2011; 650: 249-55.
60. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Aβ oligomers. J Clin Invest 2012; 122: 1339-53.
61. Huang HJ, Chen YH, Liang KC, Jheng YS, Jhao JJ, Su MT, et al. Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection. PLoS One 2012; 7: e39656.
62. Chen S, Liu AR, An FM, Yao WB, Gao XD. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4. Age (Dordr) 2012; 34: 1211-24.
63. Gault VA, Porter WD, Flatt PR, Hölscher C. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int J Obes (Lond) 2010; 34: 1341-4.
64. Tweedie D, Rachmany L, Rubovitch V, Lehrmann E, Zhang Y, Becker KG, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp Neurol 2013; 239: 170-82.
65. Holscher C. Diabetes as a risk factor for Alzheimer’s disease: insulin signalling impairment in the brain as an alternative model of Alzheimer’s disease. Biochem Soc Trans 2011; 39: 891-7.
66. McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology 2014; 76 (Pt A): 57-67.
67. Long-Smith CM, Manning S, McClean PL, Coakley MF, O’Halloran DJ, Holscher C, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signaling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer’s disease. Neuromolecular Med 2013; 15: 102-14.
68. Porter DW, Kerr BD, Flatt PR, Holscher C, Gault VA. Four weeks administration of liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab 2010; 12: 891-9.
69. Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S, et al. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis 2013; 37: 637-48.
70. McClean PL, Gault VA, Harriott P, Hölscher C. Glucagonlike peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer’s disease. Eur J Pharmacol 2010; 630: 158-62.
71. Wang XH, Li L, Hölscher C, Pan YF, Chen XR, Qi JS. Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 2010; 170: 1239-48.
72. Gengler S, McClean PL, McCurtin R, Gault VA, Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 2012; 33: 265-76.
73. Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E. Glucagonlike peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer’s disease model mice. J Neurosci 2012; 32: 13701-8.
74. Egefjord L, Gejl M, Moller A, Braendgaard H, Gottrup H, Antropova O, et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer’s disease –protocol for a controlled, randomized double-blinded trial. Dan Med J 2012; 59: A4519.